Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Rudwaleit

Showing results (111-120 of 150) with videos related to

Pageof 15
Sort By:
RMD Open|May 7, 2020
The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEWIrene van der Horst-Bruinsma, Rianne van Bentum, Frank D Verbraak, et al.
Rheumatology (Oxford, England)|April 3, 2019
Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?Miranda van Lunteren, Désirée van der Heijde, Alexandre Sepriano, et al.
Rheumatology (Oxford, England)|August 11, 2022
Comparing MRI and conventional radiography for the detection of structural changes indicative of axial spondyloarthritis in the ASAS cohortMikhail Protopopov, Fabian Proft, Stephanie Wichuk, et al.
Rheumatology and Therapy|December 19, 2025
Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X TrialsJohn D Reveille, Martin Rudwaleit, Proton Rahman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial SpondyloarthritisAtul Deodhar, Lianne S Gensler, Jonathan Kay, et al.
The Journal of Rheumatology|February 15, 2007
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitisXenofon Baraliakos, Joachim Listing, Martin Rudwaleit, et al.
RMD Open|June 4, 2024
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studiesMaureen Dubreuil, Victoria Navarro-Compán, Annelies Boonen, et al.
Rheumatology and Therapy|June 2, 2026
Efficacy of Ixekizumab in Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level: A Pooled Analysis of Phase III TrialsRaj Sengupta, Pedro M Machado, Philippe Goupille, et al.
Annals of the Rheumatic Diseases|March 24, 2012
Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trialIn-Ho Song, Christian E Althoff, Hildrun Haibel, et al.
The Journal of Rheumatology|October 6, 2005
Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experimentRobert B M Landewé, Kay-Geert A Hermann, Désirée M F M van der Heijde, et al.
Pageof 15

Showing results (111-120 of 150) with videos related to

Sort By:
Pageof 15
RMD Open|May 7, 2020
The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEWIrene van der Horst-Bruinsma, Rianne van Bentum, Frank D Verbraak, et al.
Rheumatology (Oxford, England)|April 3, 2019
Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?Miranda van Lunteren, Désirée van der Heijde, Alexandre Sepriano, et al.
Rheumatology (Oxford, England)|August 11, 2022
Comparing MRI and conventional radiography for the detection of structural changes indicative of axial spondyloarthritis in the ASAS cohortMikhail Protopopov, Fabian Proft, Stephanie Wichuk, et al.
Rheumatology and Therapy|December 19, 2025
Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X TrialsJohn D Reveille, Martin Rudwaleit, Proton Rahman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial SpondyloarthritisAtul Deodhar, Lianne S Gensler, Jonathan Kay, et al.
The Journal of Rheumatology|February 15, 2007
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitisXenofon Baraliakos, Joachim Listing, Martin Rudwaleit, et al.
RMD Open|June 4, 2024
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studiesMaureen Dubreuil, Victoria Navarro-Compán, Annelies Boonen, et al.
Rheumatology and Therapy|June 2, 2026
Efficacy of Ixekizumab in Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level: A Pooled Analysis of Phase III TrialsRaj Sengupta, Pedro M Machado, Philippe Goupille, et al.
Annals of the Rheumatic Diseases|March 24, 2012
Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trialIn-Ho Song, Christian E Althoff, Hildrun Haibel, et al.
The Journal of Rheumatology|October 6, 2005
Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experimentRobert B M Landewé, Kay-Geert A Hermann, Désirée M F M van der Heijde, et al.
Pageof 15